Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 5/20 | 0.61 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.61 |
| ▸ | AR | P10275 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8381867 | 0.87 | SRD5A2 (0.46) | SRD5A2SRD5A1AR | |
| SCHEMBL13603626 | 0.85 | SRD5A2 (0.44) | SRD5A2SRD5A1AR | |
| SCHEMBL13611186 | 0.85 | SRD5A2 (0.44) | SRD5A2SRD5A1AR | |
| SCHEMBL8536963 | 0.83 | AKR1B10 (0.61) | AR | |
| SCHEMBL8409235 | 0.83 | SRD5A1 (0.63) | SRD5A2SRD5A1 | |
| SCHEMBL7621779 | 0.83 | SRD5A1 (0.63) | SRD5A2SRD5A1 | |
| SCHEMBL7624258 | 0.81 | SRD5A2 (0.61) | SRD5A2SRD5A1AR | |
| SCHEMBL7142783 | 0.81 | SRD5A2 (0.61) | SRD5A2SRD5A1AR | |
| SCHEMBL8795547 | 0.81 | SRD5A1 (0.56) | SRD5A2SRD5A1 | |
| SCHEMBL8777183 | 0.81 | SRD5A2 (0.58) | SRD5A2SRD5A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7164022-B2 | Process for the preparation of pure Finasteride | AUROBINDO PHARMA LTD. (IN) | 2007-01-16 | — | — | US | disclosed |
| US-7164022-B2 | Process for the preparation of pure Finasteride | AUROBINDO PHARMA LTD. (IN) | 2007-01-16 | — | — | US | disclosed |
| US-6432971-B2 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO., INC. | 2001-12-06 | — | — | US | disclosed |
| US-6268376-B1 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2001-07-31 | — | — | US | disclosed |
| US-6046183-A | SYNERGISTIC MIXTURE OF FINASTERIDE AND DOXAZOSIN | MERCK & CO., INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5753641-A | SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS | MERCK & CO., INC. (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0674521-A4 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17-g(b)-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5-g(a)-ANDROST-1-EN-3-ONES. | MERCK & CO INC (US) | 1998-02-04 | — | — | EP | disclosed |
| US-5693809-A | PREGNANES FOR TREATING ALOPECIA, ACNE AND SKIN DISORDER | MERCK & CO., INC. (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0547691-B1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO INC (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0674521-A1 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17$g(b)-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5$g(a)-ANDROST-1-EN-3-ONES | MERCK & CO. INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| US-5418238-A | 17β-substituted 4-aza-5α-androstan-3-one derivatives | FARMITALIA CARLO ERBA S.R.L. (IT) | 1995-05-23 | — | — | US | disclosed |
| WO-1994015602-A1 | COMBINATION METHOD FOR TREATING PATTERNED ALOPECIA WITH 17β-N-SUBSTITUTED-CARBAMOYL-4-AZA-5α-ANDROST-1-EN-3-ONES AND MINOXIDIL | MERCK & CO., INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994014452-A1 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17β-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5α-ANDROST-1-EN-3-ONES | MERCK & CO., INC. (US) | 1994-07-07 | — | — | WO | disclosed |
| EP-0285383-B1 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO INC (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0547691-A1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| US-4760071-A | Enzyme inhibitor | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | NR5A1, CYP17A1, HSD17B7 | SRD5A2 11/4885SRD5A1 8/4885AR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.